Sotrovimab is a monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.
- Mechanism
- Curator reviewed · 3 references
Sotrovimab is a recombinant human IgG1κ monoclonal antibody that acts by binding to a conserved epitope located on the spike protein receptor-binding domain of SARS-CoV-2, the virus causing COVID-19. The epitope is highly conserved, discouraging the development of viral resistance to the antibody. This prevents the spike protein mediated binding of SARS-CoV-2 and entry into human cells. Sotrovimab does not compete with human ACE2 receptor binding and inhibits an undefined step that occurs after viral attachment and before the fusion of the viral and cell membranes. The Fc component of sotrovimab includes M428L and N434S amino acid substitutions (LS modification) that result in a longer half-life.
- Primary indication
- In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.Curator reviewed · 1 structured indication
- Formula / weight
- 149000.0 Da
- First approval
- Canada, 2021
- Code names
- GSK-4182136 · VIR-7831
Resolves to
What you can answer from here — as of September 26, 2025
Which drugs share a target with Sotrovimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account